What is PsiThera?
PsiThera is at the forefront of biotechnology innovation, dedicated to creating oral medications for immune and inflammatory diseases. By integrating biophysics, computational modeling, and mechanistic biology, the company's expert drug hunters are identifying new therapeutic targets and optimizing drug candidates. PsiThera's advanced pipeline is focused on high-value targets, with an initial emphasis on the Tumor Necrosis Factor (TNF) superfamily, a critical pathway in many inflammatory disorders. The company's approach aims to overcome the limitations of current injectable therapies, offering a more convenient and potentially more effective treatment modality.
How much funding has PsiThera raised?
PsiThera has raised a total of $47.5M across 1 funding round:
Series A
$47.5M
Series A (2025): $47.5M with participation from Lightstone Ventures, Roivant Sciences, Eurofarma, and Samsara BioCapital
Key Investors in PsiThera
Lightstone Ventures
Lightstone Ventures is a venture capital firm that supports founders in the biotech and medtech sectors, providing capital and strategic insights to transform scientific discoveries into patient treatments.
Roivant Sciences
Roivant Sciences is a tech-enabled healthcare company focused on advancing late-stage drug candidates and delivering innovative healthcare technologies, founded in 2014.
Eurofarma
Eurofarma is a company operating in the Photography Studio industry, headquartered in Santiago, Chile, with a significant employee base and revenue.
What's next for PsiThera?
With the recent infusion of major strategic capital, PsiThera is poised for accelerated growth and pipeline advancement. This significant investment is expected to fuel the progression of its drug candidates through critical development stages, potentially leading to expanded clinical trials and further research into novel therapeutic opportunities. The company's focus on integrating cutting-edge computational intelligence with deep biological understanding positions it for continued leadership in the biopharmaceutical sector, particularly in addressing unmet needs in immune and inflammatory diseases. PsiThera's strategic financing will likely enable further expansion of its research capabilities and solidify its market position.
See full PsiThera company page
